Publications

5802 Results

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma

Authors
SP Patel;M Othus;J Moon;M Tetzlaff;E Buchbinder;VK Sondak;M Lowe;K Mireles;E Sharon;L Korde;S Guild;W Carson;A Ribas;K Grossmann
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9585) (American Society of Clinical Oncology Annual Meeting 2021 (TIPS poster)
Year
2021
Research Committee(s)
Melanoma
Study Number(s)
S1801

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients: A trial of the ECOG-ACRIN Cancer Research Group (EA2176)

Authors
M Roth;P Catalana;K Ciombor;A Benson;X Yao;R Yaeger;M Salem;V Morris;D Henry;J Whisenant;P O'Dwyer;C Eng
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3614) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2176

Baseline and short-term financial burden (FB) in colorectal cancer (CRC) treated with curative intent: early results of ECOG-ACRIN EAQ162CD

Authors
S Kircher;F Duan;I Gareen;E Underwood;J Sicks;J Suga;H Kehn;P Mehan;J Acoba;M Taylor;L Wagner;R Carlos
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 1518) (American Society of Clinical Oncology Annual Meeting 2021, poster discussion session)
Year
2021
Research Committee(s)
Cancer Care Delivery

Prospective Validation of Genetic Predictors of Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS) in a Racially Diverse Cohort: Results from ECOG-ACRIN E1Z11

Authors
V Stearns;O Jegede;V Chang;T Skaar;J Berenberg;R Nand;A Lyss;N Jacobs;W Luginbuhl;P Gilman;A Benson;J Goodman;G Buchschacher;NL Henry;C Loprinzi;P Flynn;E Mitchell;MJ Fisch;J Sparano;L Wagner
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 12003) (American Society of Clinical Oncology Annual Meeting 2021, oral)
Year
2021
Research Committee(s)
Breast
Study Number(s)
CTSU/E1Z11

Phase III study of local or systemic therapy Intensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191

Authors
N Vapiwala;Y Chen;S Cho;F Duan;C Kyriakopoulos;D Shevrin;R McKay;B Koontz;E Yu;V Beylergil;D Mankoff;J McConathy;G Liu;T Wong;M Carducci
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5098) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Genitourinary

PROSPER: Phase III RandOmized Study Comparing PERioperative Nivolumab versus Observation in Patients with Renal Cell Carcinoma (RCC) Undergoing Nephrectomy (ECOG-ACRIN EA8143)

Authors
M Allaf;S Kim;V Master;D McDermott;C Drake;S Signoretti;D Cella;R Gupta;S Cole;B Shuch;P Lara;A Kapoor;D Heng;B Leibovich;M Michaelson;T Choueiri;M Jewett;D Maskens;L Harshman;M Carducci;N Haas
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4596) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8143

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN & NRG Collaboration

Authors
M Joshi;S Kim;A Solanki;D Miyamoto;D Degraff;J Zou;J Meeks;T Mitin;S Collins;E Trabulsi;N Hahn;J Efstathiou;M Carducci
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4590) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8185

A randomized phase III post-operative trial of platinum-based chemotherapy (P) vs. capecitabine (C) in patients (pts) with residual triple-negative breast (TNBC) cancer following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Authors
IA Mayer;F Zhao;C Arteaga;W Symmans;B Park;B Burnette;A Tevaarwerk;S Garcia;K Smith;E Mayer;W Sikov;E Rodler;L Wagner;A DeMichele;J Sparano;A Wolff;K Miller
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 605) (American Society of Clinical Oncology Annual Meeting 2021, LBA, oral session)
Year
2021
Research Committee(s)
Breast
Study Number(s)
CTSU/EA1131

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-Grade Neuroendocrine Neoplasm Cohort

Authors
S Patel;M Othus;YK Chae;J Strosberg;J Wang;B Konda;J Hayward;C McLeod;H Chen;E Sharon;E Mayerson;C Ryan;M Plets;CD Blanke;R Kurzrock
Journal / Conference
Cancer Sep 1;127(17):3194-3201; Apr 21. doi: 10.1002/cncr.33591. Online ahead of print
Year
2021
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID33882143
PMC
PMC8606104
Study Number(s)
S1609

Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry

Authors
M Graff;A Justice;K Young;E Marouli;X Zhang;R Fine;P Goodman;A Hsing;E Klein;M Neuhouser;L Sucheston;R Loos;M Ng;K North
Journal / Conference
American Journal of Human Genetics Apr 1;108(4):564-582. doi: 10.1016/j.ajhg.2021.02.011. Epub 2021 Mar 12.
Year
2021
Research Committee(s)
Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
PMID
PMID33713608
PMC
PMC8059339
Study Number(s)
S0000